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Neuropeptide Y (NPY), which is widely expressed in both the central and peripheral nervous systems, has an important role in
a variety of biological ﬁelds. In this study, we analyzed the distribution of NPY polymorphisms in dampness-phlegm pattern
and non-dampness-phlegm pattern in elderly Korean subjects with cerebral infarction (CI). A total of 1.097 subjects (498
normal subjects and 599 CI patients, including 198 with dampness-phlegm pattern and 401 with non-dampness-phlegm pattern)
participated in this study. Genotyping for ﬁve SNPs (G-1484A, C-1471T, C-399T, A1201G, and C5325T) was conducted by primer
extension. The results were statistically analyzed for genetic association of NPY-polymorphisms with normal versus dampness-
phlegm pattern or non-dampness-phlegm pattern subjects. Among the ﬁve SNPs tested, the T allele of C-399T has a negative
association with the dampness-phlegm pattern and is marked by a decrease in serum cholesterol levels. Furthermore, serum
cholesterollevelsweresigniﬁcantlyhigherindampness-phlegmpatternpatientsthaninnon-dampness-phlegmpatternpatients.In
this study, for the ﬁrst time, the association of NPY polymorphisms with pattern identiﬁcation (PI) of traditional Korean medicine
(TKM) was analyzed in a large CI patient population.
1.Introduction
Neuropeptide Y (NPY), ﬁrst identiﬁed in mammalian brains
in the 1980s, is a neuropeptide consisting of 36 amino acids
[1, 2] that exhibits diverse biological functions [3]. Most
of the NPY protein is secreted by the peripheral or central
nervous systems [1] and is involved in multiple physiological
processes and pathological conditions, including memory,
stress, overeating and obesity, pain regulation, neural reg-
ulation, Alzheimer’s disease, regulation of blood pressure,
and cerebral circulation [3–13]. Direct or indirect eﬀects
of NPY have been particularly implicated in obesity and
metabolicsyndromes.LargelysecretedNPYstimulateseating
and drives overeating-induced obesity [14]. Furthermore,
the expression and secretion of NPY by sympathetic nerves
andfattissuewasrecentlyshowntoactivateproliferationand
adipogenesis of preadipocytes in fat tissue [15–17].
The NPY gene, located at chromosome 7p15.1, has
twenty-ﬁve polymorphisms in its promoter region and seven
within its exons (NT 007819.17). The L7P SNP has been
associated with type 2 diabetes mellitus, alcoholism, and
obesity [18–22]. Another functional SNP, C-399T, in which
the T allele exhibits lower transcriptional activity than the C
allele, was also associated with schizophrenia [23] and non-
Hodgkin’s lymphoma [24]. Recently, Kim et al. reported that
this SNP was signiﬁcantly associated with ischemic stroke in
the Korean elderly population [25], with Yu et al. showing
the same results in Chinese subjects [26].
Traditional Korean medicine (TKM), which is similar
to traditional Chinese medicine (TCM), categorizes stroke
into internal disease symptoms. Pattern identiﬁcation (PI)
is a diagnostic system that entails a comprehensive analysis
of symptoms and signs, with implications for determining
the cause, nature, and location of the illness; the patient’s
physicalcondition;thepatient’streatment[27,28].Goprevi-
ously reported that the PI of stroke in TKM can be classiﬁed
into ﬁve types: ﬁre heat pattern, dampness-phlegm pattern,
blood stasis pattern, yin deﬁciency pattern and Qi deﬁciency
pattern [29]. Among these, subjects with dampness-phlegm
pattern tend to be obese and have hyperlipidemia [30].2 Evidence-Based Complementary and Alternative Medicine
PI is aﬀected by environmental and hereditary factors.
Some reports have suggested a relationship between genetic
variation and PI among Chinese, Korean, and Japanese
populations [31–34].
In this study, we analyzed the distribution of NPY
polymorphisms in dampness-phlegm pattern and non-
dampness-phlegm pattern in elderly Korean subjects.
2.MaterialsandMethods
2.1. Study Subjects. Patients with cerebral infarction (CI)
were admitted into twelve Korean oriental medical hospitals
participating in this study: Kyung Hee Oriental Medical
Center (Seoul), Kyung Hee East-West Neo Medical Center
(Seoul), Dong Guk International Hospital (Kyunggi-do),
KyungWonOrientalMedicalHospitals(SeoulandIncheon),
Dong Seo Oriental Medical Hospital (Seoul), Dae Jeon
Oriental Medical Hospital (Daejeon), Dong Sin Oriental
Medical Hospital (Gwangju and Jeollanam-do), Won Kwang
Oriental Medical Hospital (Jeollabuk-do), Woo Suk Orien-
tal Medical Hospital (Jeollabuk-do), and Sang Ji Oriental
Medical Hospital (Gangwon-do). CI was conﬁrmed by
magnetic resonance imaging (MRI) or magnetic resonance
angiography (MRA). After obtaining informed consent from
all subjects, clinical data were collected, and syndromes were
diﬀerentiated classiﬁed using “stroke PI case report form.”
PI diagnosis of each patient was determined by two expert
TKM doctors, and subjects receiving diﬀering opinions from
two doctors were excluded [27]. Patients with histories of
transient ischemic attack (TIA), diabetes, hyperlipidemia,
and heart disease were excluded, as were patients with a
previous stroke or a traumatic stroke.
Normal subjects were recruited from Dae Jeon Ori-
ental Medical Hospital and Won Kwang Oriental Medi-
cal Hospital, and stroke status was conﬁrmed by MRI.
Subjects with a history of stroke, TIA, diabetes, hyper-
lipidemia and heart disease were excluded. Four hundred
ninety-eight normal subjects and ﬁve hundred ninety-nine
CI patients classiﬁed as having dampness-phlegm pattern
(N = 198) or non-dampness-phlegm pattern (N = 401)
participated in this study. The general characteristics of
normal subjects and CI patients are shown in Supplemental
Table 1 (See in Supplementary Material available online
at doi:10.1155/2012/109796.). This study was approved by
the Institutional Review Boards of the Korean institute of
Oriental Medicine and by each of the Oriental Medical
Hospitals.
2.2. Preparation of Genomic DNA and Identiﬁcation of
SNPs. Genomic DNA of each subject was extracted from
whole blood using a GeneAll Genomic DNA Extraction Kit
(GeneAll, Seoul, Korea). The promoter region (2kb) and all
exonsoftheNPYgeneweresequencedin24Koreangenomic
DNA samples using an ABI PRISM 3700 DNA analyzer
(Applied Biosystems, Foster City, Calif, USA). Primer sets
used in the ampliﬁcation and sequencing analyses were
designed on the basis of the reference genome sequence for
NPY (NC 000007). Information concerning the primers for
the ampliﬁcation and sequencing of the NPY gene is shown
in Supplemental Table 2.
Genotyping of SNPs in all subjects was conducted using
the SNaPshot multiplex system (Applied Biosystem, Foster-
City, CA, USA) according to the manufacturer’s protocol.
PrimerandNPYSNPgenotypingprobesequencesareshown
in Supplemental Table 3.
Hardy-Weinberg equilibrium tests were employed to
determine whether individual SNPs were in equilibrium at
eachlocus,andlinkagedisequilibrium(LD)coeﬃcients, |D |
and r2, were evaluated to measure LD between all pairs of
loci [35]. The frequencies of SNPs and LD coeﬃcients were
inferred using the HapAnalyzer program v1.0.
2.3. Statistical Analysis. Data were statistically analyzed with
SAS software, version 9.1.3 (SAS Institute Inc., Cary, NC).
All continuous variables were subjected to a Kolmogorov-
Smirnov normality test. Diﬀerences in continuous vari-
ables were determined by parametric (Student’s t-test) or
nonparametric (Wilcoxon rank sum test) test. Categorical
variables were compared with a chi-square test or Fisher’s
exact test.
Multiplelogisticregressionadjustedforage,sex,smoking
status, and drinking status was performed to estimate the
association of SNPs with normal versus dampness-phlegm
pattern (or non-dampness-phlegm pattern), as well as odds
ratios (ORs) with 95% conﬁdence intervals (95% CI). To
investigate whether the C-399T polymorphism is associated
with the clinical parameters of the normal subjects, we
performed a statistical analysis using a general linear model
adjusted for age, sex, smoking status, and drinking status.
Statistical signiﬁcance was set at P<0.05.
3. Results
General characteristics of normal and CI patients are shown
in Supplemental Table 1 and are similar to our previous
study [25]. The clinical diﬀerences between the CI patients
classiﬁed as dampness-phlegm pattern or non-dampness-
phlegm pattern according to the PI of TKM are shown in
Table 1. The mean waist circumference of the dampness-
phlegm pattern patients was signiﬁcantly higher than that
of the normal subjects (P<0.001). A higher mean waist
circumference was also observed in the dampness-phlegm
pattern group compared with the non-dampness-phlegm
pattern group. Additionally, serum lipids, total cholesterol
and LDL-cholesterol levels were higher in the dampness-
phlegm pattern group than in the non-dampness-phlegm
pattern group.
The location of ﬁve SNPs within the NPY gene are
shown in Figure 1(a), and their characteristics is listed in
Table 2. Three of these SNPs are in the NPY promoter,
one is in exon 2, and the other is in exon 3. None of the
alleles result in an amino acid change. All of the alleles
were in Hardy-Weinberg equilibrium (P>0.01) accord-
ing to the recommended International HapMap Project
guidelines. The LD coeﬃcients between the ﬁve SNPs areEvidence-Based Complementary and Alternative Medicine 3
Table 1: Demographic parameters of study subjects.
Characteristics Normal Non-dampness-phlegm sig.a Dampness-phlegm sig.b
N 498 401 198
Anthropometric characteristics
Sex (M/F) 215/283 226/175 <.0001 104/94 <.05
Age (year) 60.76 ±9.77 67.02 ±11.94 <.0001 64.7±12.81 <.0001
Smoking (none/stop/active) 241/214/43 216/81/104 <.0001 117/21/60 <.0001
Drinking (none/stop/active) 298/31/168 199/59/143 <.0001 114/14/69 NS
WHR 0.88 ±0.06 0.93 ±0.07 <.0001 0.93 ±0.05 <.0001
Waist circumference (cm) 83.61 ±8.38 84.61 ±9.79 NS 87.13 ±9.82 <.001
TOAST classiﬁcation
LAA — 64 ND 30 ND
CE — 15 8
SVO — 237 123
SOE — 9 2
SUE — 14 4
Medical history
Hypertension (Yes, %) 60 (12.07) 217 (54.94) <.0001 120 (60.61) <.0001
Blood parameter
GOP (U/mL) 27.56 ±19.97 27.31 ±22.5N S 2 6 .08 ±16.07 NS
GPT (U/mL) 26.04 ±20.26 25.6 ±24.29 NS 26.19 ±23.37 NS
Total cholesterol (mg/dL) 202.23 ±40.04 181.5 ±43.68 <.0001 192.83 ±43.95 <.01
Triglyceride (mg/dL) 139.88 ±69.80 149.86 ±95.72 NS 150.75 ±101.28 NS
HDL-cholesterol (mg/dL) 52.28 ±12.69 46.1 ±14.33 <.0001 44.57 ±12.44 <.0001
LDL-cholesterol (mg/dL) 121.19 ±36.70 109.42 ±36.75 <.0001 121.21 ±40.35 NS
Bloog sugar (mg/dL) 99.75 ±10.79 112.05 ±34.48 <.0001 109.81 ±29.53 <.0001
All results except sex, TOAST categories, smoking, drinking, and hypertension are expressed as mean ± SD for continuous variables. NS: not signiﬁcant. ND:
not done. WHR: waist hip ratio. TOAST: trial of ORG 10172 in acute stroke treatment. LAA: large-artery atherosclerosis. CE: cardioembolism. SVO: small-
vessel occlusion. SOE: stroke of other etiology. SUE: stroke of undetermined etiology. GOP: glutamate oxaloacetate transaminase. GPT: glutamate pyruvate
transaminase. sig.a: P value of normal versus non-dampness-phlegm using a Student’s t-test or Wilcoxon rank-sum test in continuous variables, chi-square
test, or Fisher’s exact test in categorical variables. sig.b: P value of normal versus dampness-phlegm using a Student’s t-test or Wilcoxon rank sum test in
continuous variables, chi-square test, or Fisher’s exact test in categorical variables. P values with statistical signiﬁcance were presented in bold.
Table 2: Characteristics of SNPs identiﬁed by genomic sequencing of the promoter, exon of NPY in normal group.
SNP rs no. Position Location relative to
transcription start site
Nucleotide
change
Location relative to p
terminus of chromosome
Minor allele
frequency HWE p
G-1484A rs16149 Promoter −2535 G>A 24,322,325 0.314 0.2624
C-1471T rs16148 Promoter −2522 C>T 24,322,338 0.171 0.2733
C-399T rs16147 Promoter −1450 C>T 24,323,410 0.331 0.0709
A1201G rs5573 Exon 2 150 A>G 24,325,009 0.342 0.0417
C5325T rs5574 Exon 3 4274 C>T 24,329,133 0.314 0.1836
shown in Figure 1(b). Among these, G-1484A, C-399T,
and A1201G were slightly linked (|D |=1a n dr2 =
0.862–0.951).
Table 3 shows the SNP distribution in the non-
dampness-phlegm pattern and the dampness-phlegm pat-
terngroupscomparedwiththenormalgroup.Thefrequency
of T allele of C-399T is 27.27% in dampness-phlegm pattern,
which is signiﬁcantly lower than in normal (33%) and non-
dampness-phlegm pattern patients (45.96%), as adjusted for
sex, age, smoking, drinking and hypertension [P = 0.0378,
OR = 0.737 (0.552–0.983)]. The ratio of subjects with
T allele in the dampness-phlegm pattern group (45.96%)
is also smaller than in the normal (53.25%) and non-
dampness-phlegm pattern groups (56.0%) [P = 0.0315,
OR = 0.663 (0.456–0.964)]. In contrast, subjects with T
allele of C5325T at exon 3 exhibited signiﬁcantly more
dampness-phlegm pattern than normal and non-dampness-
phlegm pattern in the dominant model.
Table 4 shows the comparison of obesity phenotypes
and serum lipids in C-399T genotypes. The level of total
c h o l e s t e r o la n dL D L - c h o l e s t e r o li nn o r m a ls u b j e c t sw i t hT T
type at C-399T was signiﬁcantly lower than subjects with
Ca l l e l e( P = 0.0111 and P = 0.0186, resp.). Conversely,
triglycerides were slightly increased in the dominant model.4 Evidence-Based Complementary and Alternative Medicine
T
a
b
l
e
3
:
G
e
n
o
t
y
p
e
d
i
s
t
r
i
b
u
t
i
o
n
o
f
N
P
Y
p
o
l
y
m
o
r
p
h
i
s
m
o
f
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
a
n
d
n
o
n
-
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
.
M
o
d
e
l
S
N
P
s
G
e
n
o
t
y
p
e
N
o
r
m
a
l
N
o
n
-
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
c
O
R
[
9
5
%
C
I
]
s
i
g
.
a
D
a
m
p
n
e
s
s
-
p
h
l
e
g
m
d
O
R
[
9
5
%
C
I
]
s
i
g
.
b
A
l
l
e
l
e
G
-
1
4
8
4
A
G
6
8
2
(
6
8
.
7
5
)
5
4
4
(
6
8
)
0
.
9
8
8
0
.
9
1
4
5
2
9
4
(
7
4
.
2
4
)
0
.
7
4
8
0
.
0
5
2
4
A
3
1
0
(
3
1
.
2
5
)
2
5
6
(
3
2
)
[
0
.
7
8
7
,
1
.
2
4
0
]
1
0
2
(
2
5
.
7
6
)
[
0
.
5
5
8
,
1
.
0
0
3
]
C
-
1
4
7
1
T
C
8
2
4
(
8
2
.
9
0
)
6
6
3
(
8
3
.
2
9
)
1
.
0
5
1
0
.
7
3
1
4
3
2
3
(
8
1
.
9
8
)
0
.
9
3
1
0
.
6
8
6
7
T
1
7
0
(
1
7
.
1
0
)
1
3
3
(
1
6
.
7
1
)
[
0
.
7
9
1
,
1
.
3
9
8
]
7
1
(
1
8
.
0
2
)
[
0
.
6
5
6
,
1
.
3
2
0
]
C
-
3
9
9
T
C
6
6
6
(
6
7
.
0
)
5
3
5
(
6
6
.
8
8
)
1
.
0
0
7
0
.
9
5
1
1
2
8
8
(
7
2
.
7
3
)
0
.
7
3
7
0
.
0
3
7
8
T
3
2
8
(
3
3
.
0
)
2
6
5
(
3
3
.
1
3
)
[
0
.
8
0
4
,
1
.
2
6
1
]
1
0
8
(
2
7
.
2
7
)
[
0
.
5
5
2
,
0
.
9
8
3
]
A
1
2
0
1
G
A
6
5
3
(
6
5
.
8
3
)
4
9
7
(
6
2
.
1
3
)
0
.
8
6
8
0
.
2
0
9
9
2
7
2
(
6
8
.
6
9
)
0
.
8
7
9
0
.
3
6
6
6
G
3
3
9
(
3
4
.
1
7
)
3
0
3
(
3
7
.
8
8
)
[
0
.
6
9
6
,
1
.
0
8
3
]
1
2
4
(
3
1
.
3
1
)
[
0
.
6
6
4
,
1
.
1
6
3
]
C
5
3
2
5
T
C
6
8
2
(
6
8
.
7
5
)
5
3
4
(
6
6
.
7
5
)
0
.
8
5
1
0
.
1
6
5
8
2
5
0
(
6
3
.
1
3
)
1
.
2
5
0
0
.
1
1
3
1
T
3
1
0
(
3
1
.
2
5
)
2
6
6
(
3
3
.
2
5
)
[
0
.
6
7
8
,
1
.
0
6
9
]
1
4
6
(
3
6
.
8
7
)
[
0
.
9
4
8
,
1
.
6
4
8
]
†
D
o
G
-
1
4
8
4
A
G
G
2
4
0
(
4
8
.
3
9
)
1
8
1
(
4
5
.
2
5
)
0
.
9
3
0
.
6
3
6
3
1
1
0
(
5
5
.
5
6
)
0
.
6
9
7
0
.
0
5
8
3
G
A
+
A
A
2
5
6
(
5
1
.
6
1
)
2
1
9
(
5
4
.
7
5
)
[
0
.
6
8
8
,
1
.
2
5
7
]
8
8
(
4
4
.
4
4
)
[
0
.
4
8
0
,
1
.
0
1
3
]
C
-
1
4
7
1
T
C
C
3
3
8
(
6
8
.
0
1
)
2
7
6
(
6
9
.
3
5
)
1
.
0
5
8
0
.
7
3
1
9
1
3
5
(
6
8
.
5
3
)
0
.
9
1
8
0
.
6
7
6
2
C
T
+
T
T
1
5
9
(
3
1
.
9
9
)
1
2
2
(
3
0
.
6
5
)
[
0
.
7
6
5
,
1
.
4
6
5
]
6
2
(
3
1
.
4
7
)
[
0
.
6
1
4
,
1
.
3
7
3
]
C
-
3
9
9
T
C
C
2
3
2
(
4
6
.
6
8
)
1
7
6
(
4
4
)
0
.
9
5
3
0
.
7
5
6
9
1
0
7
(
5
4
.
0
4
)
0
.
6
6
3
0
.
0
3
1
5
C
T
+
T
T
2
6
5
(
5
3
.
3
2
)
2
2
4
(
5
6
)
[
0
.
7
0
5
,
1
.
2
9
]
9
1
(
4
5
.
9
6
)
[
0
.
4
5
6
,
0
.
9
6
4
]
A
1
2
0
1
G
A
A
2
2
5
(
4
5
.
3
6
)
1
5
8
(
3
9
.
5
)
0
.
8
2
1
0
.
2
0
5
9
9
5
(
4
7
.
9
8
)
0
.
8
6
2
0
.
4
3
5
7
A
G
+
G
G
2
7
1
(
5
4
.
6
4
)
2
4
2
(
6
0
.
5
)
[
0
.
6
0
5
,
1
.
1
1
4
]
1
0
3
(
5
2
.
0
2
)
[
0
.
5
9
4
,
1
.
2
5
2
]
C
5
3
2
5
T
C
C
2
4
1
(
4
8
.
5
9
)
1
7
9
(
4
4
.
7
5
)
0
.
7
9
4
0
.
1
3
3
5
7
6
(
3
8
.
3
8
)
1
.
5
5
7
0
.
0
2
1
0
C
T
+
T
T
2
5
5
(
5
1
.
4
1
)
2
2
1
(
5
5
.
2
5
)
[
0
.
5
8
7
,
1
.
0
7
3
]
1
2
2
(
6
1
.
6
2
)
[
1
.
0
6
9
,
2
.
2
6
9
]
†
R
G
-
1
4
8
4
A
G
G
+
G
A
4
4
2
(
8
9
.
1
1
)
3
6
3
(
9
0
.
7
5
)
1
.
1
4
8
0
.
5
8
6
8
1
8
4
(
9
2
.
9
3
)
0
.
7
0
0
0
.
2
9
6
1
A
A
5
4
(
1
0
.
8
9
)
3
7
(
9
.
2
5
)
[
0
.
6
9
7
,
1
.
8
9
]
1
4
(
7
.
0
7
)
[
0
.
3
5
9
,
1
.
3
6
6
]
C
-
1
4
7
1
T
C
C
+
C
T
4
8
6
(
9
7
.
7
9
)
3
8
7
(
9
7
.
2
4
)
1
.
0
7
7
0
.
8
8
2
6
1
8
8
(
9
5
.
4
3
)
0
.
9
3
7
0
.
9
0
1
9
T
T
1
1
(
2
.
2
1
)
1
1
(
2
.
7
6
)
[
0
.
4
0
4
,
2
.
8
6
8
]
9
(
4
.
5
7
)
[
0
.
3
3
0
,
2
.
6
5
6
]
C
-
3
9
9
T
C
C
+
C
T
4
3
4
(
8
7
.
3
2
)
3
5
9
(
8
9
.
7
5
)
1
.
1
5
7
0
.
5
4
4
4
1
8
1
(
9
1
.
4
1
)
0
.
7
5
0
0
.
3
5
7
9
T
T
6
3
(
1
2
.
6
8
)
4
1
(
1
0
.
2
5
)
[
0
.
7
2
2
,
1
.
8
5
3
]
1
7
(
8
.
5
9
)
[
0
.
4
0
6
,
1
.
3
8
5
]
A
1
2
0
1
G
A
A
+
A
G
4
2
8
(
8
6
.
2
9
)
3
3
9
(
8
4
.
7
5
)
0
.
8
6
9
0
.
5
1
8
1
7
7
(
8
9
.
3
9
)
0
.
8
3
0
0
.
5
2
0
1
G
G
6
8
(
1
3
.
7
1
)
6
1
(
1
5
.
2
5
)
[
0
.
5
6
8
,
1
.
3
3
]
2
1
(
1
0
.
6
1
)
[
0
.
4
6
9
,
1
.
4
6
6
]
C
5
3
2
5
T
C
C
+
C
T
4
4
1
(
8
8
.
9
1
)
3
5
5
(
8
8
.
7
5
)
0
.
8
7
8
0
.
5
9
6
6
1
7
4
(
8
7
.
8
8
)
0
.
9
0
7
0
.
7
4
5
7
T
T
5
5
(
1
1
.
0
9
)
4
5
(
1
1
.
2
5
)
[
0
.
5
4
4
,
1
.
4
1
9
]
2
4
(
1
2
.
1
2
)
[
0
.
5
0
3
,
1
.
6
3
6
]
D
a
t
a
a
r
e
p
r
e
s
e
n
t
e
d
a
s
f
r
e
q
u
e
n
c
i
e
s
(
p
e
r
c
e
n
t
a
g
e
s
)
.
c
O
R
s
a
f
t
e
r
a
d
j
u
s
t
m
e
n
t
f
o
r
s
e
x
,
a
g
e
,
d
r
i
n
k
i
n
g
,
a
n
d
s
m
o
k
i
n
g
w
i
t
h
n
o
r
m
a
l
v
e
r
s
u
s
n
o
n
-
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
.
d
O
R
s
a
f
t
e
r
a
d
j
u
s
t
m
e
n
t
f
o
r
s
e
x
,
a
g
e
,
d
r
i
n
k
i
n
g
,
a
n
d
s
m
o
k
i
n
g
w
i
t
h
n
o
r
m
a
l
v
e
r
s
u
s
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
.
s
i
g
.
a
:
P
v
a
l
u
e
o
f
n
o
r
m
a
l
v
e
r
s
u
s
n
o
n
-
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
u
s
i
n
g
m
u
l
t
i
p
l
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
n
a
l
y
s
i
s
.
s
i
g
.
b
:
P
v
a
l
u
e
o
f
n
o
r
m
a
l
v
e
r
s
u
s
d
a
m
p
n
e
s
s
-
p
h
l
e
g
m
u
s
i
n
g
m
u
l
t
i
p
l
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
n
a
l
y
s
i
s
.
†
D
o
a
n
d
R
d
e
n
o
t
e
d
o
m
i
n
a
n
t
a
n
d
r
e
c
e
s
s
i
v
e
m
o
d
e
l
s
,
r
e
s
p
e
c
t
i
v
e
l
y
.
C
I
:
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
.
P
-
v
a
l
u
e
s
w
i
t
h
s
t
a
t
i
s
t
i
c
a
l
s
i
g
n
i
ﬁ
c
a
n
c
e
w
e
r
e
p
r
e
s
e
n
t
e
d
i
n
b
o
l
d
(
<
0
.
0
5
)
.Evidence-Based Complementary and Alternative Medicine 5
−
1
4
8
4
G
>
A
−
1
4
7
1
C
>
T
−
3
9
9
C
>
+
1
2
0
1
 
A
>
G
+
5
3
2
5
 
C
T
Transcription
startsite (+1)
5’ 3’
T
(a)
r2
|D|
G-1484A
G-1484A
C-1471T
C-1471T
C-399T
C-399T
A1201G
A1201G
C5325T
C5325T
0.094
0.888
0.862
0.209
1.000
0.083
0.407
0.980
0.904
0.951
0.226
0.90
0.8 5 7
1.000
0.225
1.000
0.949
1.000
0.973 0. 2 08
(b)
Figure 1: Polymorphism in NPY. (a) Location of SNPs. Open box and closed box represent non translated region and translated region,
respectively. Primers for genomic ampliﬁcation and sequencing are shown below the gene map. (b) Linkage coeﬃciency among ﬁve SNPs of
NPY.
Table 4: Association of NPY polymorphism (C-399T) with clinical parameters of normal subjects.
Variable Genotype P
CC (n = 232) CT (n = 202) TT (n = 63) †Co †Do †R
Waist 82.8 ±8.43 84.46 ±8.58 3 .58 ±7.47 0.4988 0.3007 0.8857
WHR 0.88 ±0.07 0.88 ±0.05 0.87 ±0.05 0.4535 0.3418 0.2656
Total cholesterol 199.27 ±37.97 209.11 ±42.71 190.79 ±35.25 0.0019 0.1748 0.0111
Triglyceride 132.15 ±66.49 147.14 ±74.71 143.49 ±63.13 0.0869 0.03 0.697
HDL-cholesterol 52.9 ±13.05 52.79 ±12.55 50.89 ±11.86 0.3289 0.3076 0.1666
LDL-cholesterol 119.32 ±35.21 126.38 ±39.09 111.2 ±31.91 0.0076 0.2913 0.0186
Blood sugar 99.33 ±9.77 99.95 ±11.63 100.7 ±11.76 0.4249 0.1984 0.4885
Data are presented as mean ± S.D. P values adjusted odds ratio, adjustment for sex, age, drinking, and smoking using a general linear model. Statistical
signiﬁcance was presented in bold (<0.05). †Co, Do, and R denote codominant, dominant, and recessive models, respectively.
4. Discussion
PI is the basic system for diagnosis of patients in TKM,
and it entails a systematic analysis of the patient’s physical
condition with implications for determination of the cause,
nature, location, and treatment of the illness. The PI can lead
TKM doctors to provide their patients with individualized
treatment, thereby increasing the eﬀectiveness of TKM and
minimizing its adverse eﬀects.
In Korea, several questionnaires for the standardization
of PI have been developed, the recent establishment of ﬁve
standard PI subtypes for stroke: ﬁre heat pattern, dampness-
phlegm pattern, blood stasis pattern, Yin deﬁciency pattern
and Qi deﬁciency pattern [29, 36]. Among these, the
dampness-phlegmpatternischaracterizedbyitsimpediment
to Qi movement and its turbidity, heaviness, stickiness, and
downward-ﬂowingproperties[17].M oreov er ,K imetal.[27]
reported that pale tongue, slippery pulse, and overweight
status are major factors positively associated with dampness-
phlegm pattern. Other studies showed that Korean stroke
patientswithdampness-phlegmpatternhadincreasedserum
cholesterollevels[30].Wealsoobtainedsimilarresultsinthis
study (Table 1). Collectively, these factors suggest that genes
or genetic variation related with obesity might be associated
with dampness-phlegm pattern in stroke.
In the current study, we examined the association of the
dampness-phlegm pattern of stroke with ﬁve SNPs of the
NPY gene among Korean CI patients and found that the C-
399T SNP was negatively associated with dampness-phlegm
pattern (OR = 0.663) (Table 3).
NPY, which is widely expressed in both the central and
peripheral nervous systems, has an important role in the
hypothalamic regulation of energy balance by stimulating
food intake and favoring energy storage through increased
lipoprotein lipase activity in white adipose tissue [14].
Many groups have studied the association of NPY
polymorphisms with obesity and/or serum lipid levels.
Karvonen et al. [37] reported that the presence of the P
allele of L7P SNP was associated with higher serum levels
of total and LDL-cholesterol in obese and normal-weight
subjects, and others have shown that L7P SNP is associated
with increased body mass index (BMI) [38]. However, this
polymorphism has not been found in Asian populations
[39, 40].
Plasma NPY level is positively correlated with total
c h o l e s t e r o la n dL D L - c h o l e s t e r o ll e v e l s[ 41], and our results
show that the C-399T SNP is signiﬁcantly associated with
decreased serum total cholesterol and LDL-cholesterol in
normal subjects (Table 4). Recently, four studies found that
the C-399T SNP aﬀects NPY level. We previously reported
that the T allele of C-399T decreases NPY transcriptional
activity and that the plasma NPY level of subjects with the
TT type was signiﬁcantly decreased compared with subjects
with the CC or CT type [25]. In addition, three other6 Evidence-Based Complementary and Alternative Medicine
groups documented the allele-speciﬁc eﬀects of the C-399T
polymorphism on NPY gene expression [42, 43]. Taken
together, these data suggest that subjects with the TT type
of C-399T may have lower levels of serum total cholesterol
and LDL-cholesterol, due to decreased plasma NPY levels.
In this study, for the ﬁrst time, the association of NPY
polymorphisms with PI of TKM was analyzed in a large CI
patient population. Among the ﬁve SNPs, the T allele of
C-399T has a negative association with dampness-phlegm
pattern by decreased levels of serum cholesterol, which were
signiﬁcantly higher in dampness-phlegm pattern patients
compared with non-dampness-phlegm pattern patients. It is
clear that the ﬁndings of this study should be interpreted
within the context of its limitations. Our ﬁndings are not
appropriate for extrapolation to the general population.
The observed associations, therefore, will require further
conﬁrmation in other subject groups.
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